Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review

References

• von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-603
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006;24(3 Suppl):S3/11-25
   Google Scholar
• Wallboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19
   PubMed Web of Science ®Google Scholar
• Aubin F, Prétet JL, Jacquard AC, et al. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 2008;47:610-5
   PubMed Web of Science ®Google Scholar
• Donne AJ, Hampson L, Homer JJ, et al. The role of HPV type in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2010;74:7-14
   PubMed Web of Science ®Google Scholar
• De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124:1626-36
   PubMed Web of Science ®Google Scholar
• Gillison M. HPV and its effect on head and neck cancer prognosis. Clin Adv Hematol Oncol 2010;8:680-2
   Google Scholar
• Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008;26(10 Suppl):K17-28
   Google Scholar
• de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004;324:17-27
   PubMed Web of Science ®Google Scholar
• Kirrander P, Kolaric A, Helenius G, et al. Human papillomavirus prevalence, distribution and correlation to histopathological parameters in a large Swedish cohort of men with penile carcinoma. BJU Int 2011;108:355-9
   PubMed Web of Science ®Google Scholar
• Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32
   PubMed Web of Science ®Google Scholar
• Acay R, Rezende N, Fontes A, et al. Human papillomavirus as a risk factor in oral carcinogenesis: a study using in situ hybridization with signal amplification. Oral Microbiol Immunol 2008;23:271-4
   PubMedGoogle Scholar
• Yanofsky VR, Patel RV, Goldenberg G. Genital warts: a comprehensive review. J Clin Aesthet Dermatol 2012;5:25-36
   PubMedGoogle Scholar
• Sanchez GI, Jaramillo R, Cuello G, et al. Human papillomavirus genotype detection in recurrent respiratory papillomatosis (RRP) in Colombia. Head Neck 2013;35:229-34
   Google Scholar
• Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Castellsagué X, de Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-86
   PubMed Web of Science ®Google Scholar
• Ting J, Kruzikas DT, Smith JS. A global review of age–specific and overall prevalence of cervical lesions. Int J Gynecol Cancer 2010;20:1244-9
   PubMed Web of Science ®Google Scholar
• Arveux P, Bénard S, Bouée S, et al. [Invasive cervical cancer treatment costs in France]. Bull Cancer 2007;94:219-24 [Article in French]
   PubMed Web of Science ®Google Scholar
• Ricciardi A, Largeron N, Giorgi Rossi P, et al. Incidence of invasive cervical cancer and direct costs associated with its management in Italy. Tumori 2009;95:146-52
   Google Scholar
• Brown RE, Breugelmans JG, Theodoratou D, et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22:663-70
   PubMed Web of Science ®Google Scholar
• Robinson D, Coupland V, Møller H. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer 2009;100:527-31
   PubMed Web of Science ®Google Scholar
• Nielsen A, Munk C, Kjaer SK. Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. Int J Cancer 2012;130:1168-73
   PubMed Web of Science ®Google Scholar
• Ramqvist T, Dalianis T. An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. Anticancer Res 2011;31:1515-9
   PubMed Web of Science ®Google Scholar
• Attner P, Du J, Näsman A, et al. The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer 2010;126:2879-84
   PubMed Web of Science ®Google Scholar
• Mehanna H, Jones TM, Gregoire V, et al. Oropharyngeal carcinoma related to human papillomavirus. BMJ 2010;340:c1439
   PubMedGoogle Scholar
• Hartwig S, Syrjänen S, Dominiak-Felden G, et al. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 2012;12:30
   PubMed Web of Science ®Google Scholar
• Karnon J, Jones R, Czoski-Murray C, et al. Cost-utility analysis of screening high-risk groups for anal cancer. J Public Health 2008;30:293-304
   Google Scholar
• Czoski-Murray C, Karnon J, Jones R, et al. Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer. Health Technol Assess 2010;14:1-131
   Google Scholar
• Abramowitz L, Rémy V, Vainchtock A. Economic burden of anal cancer management in France. Rev Epidemiol Sante Publique 2010;58:331-8
   PubMedGoogle Scholar
• Rémy V, Vainchtock A. Hospitalisation and management costs of patients with penile cancer in France. Paris, France: European Academy of Dermatology and Venereology (EADV), 2008 [Poster presentation]
   Google Scholar
• Rémy V, Mathevet P, Largeron N, et al. Cost of management of vulvar and vaginal cancers in France. Journal d’Economie Médicale 2010;28:31-45
   Google Scholar
• Mignogna MD, Fedele S, Lo Russo L, et al. Costs and effectiveness in the care of patients with oral and pharyngeal cancer: analysis of a paradox. Eur J Cancer Prev 2002;11:205-8
   PubMedGoogle Scholar
• Speight PM, Palmer S, Moles DR, et al. The cost-effectiveness of screening for oral cancer in primary care. Health Technol Assess 2006;10:1-144
   PubMedGoogle Scholar
• Kim K, Amonkar MM, Högberg D, et al. Economic burden of resected squamous cell carcinoma of the head and neck in an incident cohort of patients in the UK. Head Neck Oncol 2011;3:1-10
   Google Scholar
• Selke B, Allenet B, Bercez C, et al. [Economic assessments of head and neck cancers: a review]. Bull Cancer 2001;88:759-64 [Article in French]
   Google Scholar
• Kim K, Faivre P, Cancalon C, et al. Healthcare utilisation and costs of resected squamous cell carcinoma of head and neck (SCCHN) in France. Barcelona, Spain: European Society for Therapeutic Radiology and Oncology (ESTRO), 2010 [Poster presentation]
   Google Scholar
• Lacau St Guily JL, Borget I, Vainchtock A, et al. Head and neck cancers in France: an analysis of the hospital medical information system (PMSI) database. Head Neck Oncol 2010;2:22
   PubMedGoogle Scholar
• Ruff LK, Volmer T, Nowak D, et al. The economic impact of smoking in Germany. Eur Respir J 2000;16:385-90
   Google Scholar
• van Agthoven M, van Ineveld BM, de Boer MF, et al. The costs of head and neck oncology: primary tumours, recurrent tumours and long-term follow-up. Eur J Cancer 2001;37:2204-11
   PubMedGoogle Scholar
• Nijdam W, Levendag P, Noever I, et al. Cancer in the oropharynx: cost calculation of different treatment modalities for controlled primaries, relapses and grade III/IV complications. Radiother Oncol 2005;77:65-72
   Google Scholar
• van Agthoven M, Heule-Dieleman HAG, Knegt PP, et al. Compliance and efficiency before and after implementation of a clinical practice guideline for laryngeal carcinomas. Eur Arch Otorhinolaryngol 2006;263:729-37
   Google Scholar
• Zavras A, Andreopoulos N, Katsikeris N, et al. Oral cancer treatment costs in Greece and the effect of advanced disease. BMC Public Health 2002;2:12
   Google Scholar
• Olsen J. Incidence and costs of anal, penile, vaginal, vulva and head and neck cancer in Denmark. Lisbon, Portugal: European Research Organisation on Genital Infection and Neoplasia (EUROGIN), 2011 [Oral presentation]
   Google Scholar
• Jit M, Chapman R, Hughes O, et al. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011;343:d5775
   PubMed Web of Science ®Google Scholar
• Borget I, Abramowitz L, Mathevet P. Economic burden of HPV-related cancers in France. Vaccine 2011;29:5245-9
   PubMed Web of Science ®Google Scholar
• Rémy V, Heitland W, Klussmann J, et al. Economic burden of HPV-related head & neck and anal cancers in Germany. Value Health 2011;14:A443
   Google Scholar
• Santana R, Lopes S, Costa C. Human papillomavirus disease burden in Portugal. Lisbon, Portugal: European Research Organisation on Genital Infection and Neoplasia (EUROGIN), 2011 [Poster presentation]
   Google Scholar
• Bongers V, Hobbelink MG, van Rijk PP, et al. Cost-effectiveness of dual-head 18F-fluorodeoxyglucose PET for the detection of recurrent laryngeal cancer. Cancer Biother Radiopharm 2002;17:303-6
   Google Scholar
• Baujat B, Altabaa K, Meyers M, et al. Medicoeconomic study of microsurgical head and neck reconstructions. Eur Ann Otorhinolaryngol Head Neck Dis 2011;128:121-6
   Google Scholar
• Hopper C, Niziol C, Sidhu M. The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UK. Oral Oncol 2004;40:372-82
   PubMed Web of Science ®Google Scholar
• Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland and the United Kingdom. Value Health 2008;11:791-9
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Ekman M, Ericsson SR, et al. Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol 2005;44:850-61
   PubMed Web of Science ®Google Scholar
• Bonastre MJ, Noël E, Bensadoun RJ, et al. The cost of intensity modulated radiation therapy in head and neck cancers: results of the 2002 STIC study. Bull Cancer 2006;93:1026-32
   Google Scholar
• Nijdam W, Levendag P, Noever I, et al. Cost analysis comparing brachytherapy versus surgery for primary carcinoma of the tonsillar fossa and/or soft palate. Int J Radiat Oncol Biol Phys 2004;59:488-94
   PubMedGoogle Scholar
• Leon X, Quer M, Orus C, et al. How much does it cost to preserve a larynx? An economic study. Eur Arch Otorhinolaryngol 2000;257:72-6
   Google Scholar
• Watters K, O’Dwyer TP, Rowley H. Cost and morbidity of MRSA in head and neck cancer patients: what are the consequences? J Laryngol Otol 2004;118:694-9
   PubMed Web of Science ®Google Scholar
• Penel N, Lefebvre JL, Cazin JL, et al. Additional direct medical costs associated with nosocomial infections after head and neck cancer surgery: a hospital-perspective analysis. Int J Oral Maxillofac Surg 2008;37:135-9
   Google Scholar
• Bennett CL, Lane D, Stinson T, et al. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest 2001;19:107-13
   PubMed Web of Science ®Google Scholar
• Preuss SF, Quante G, Semrau R, et al. An analysis of surgical complications, morbidity, and cost calculation in patients undergoing multimodal treatment for operable oropharyngeal carcinoma. Laryngoscope 2007;117:101-5
   Google Scholar
• Braaksma M, van Agthoven AM, Nijdam W, et al. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomized for radioprotection with amifostine. Eur J Cancer 2005;41:2102-11
   PubMed Web of Science ®Google Scholar
• Hampl M, Huppertz E, Schulz-Holstege O, et al. Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centre. BMC Infect Dis 2011;11:73
   PubMed Web of Science ®Google Scholar
• Olsen J, Jørgensen TR, Kofoed K, et al. Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark. BMC Public Health 2012;12:1082
   PubMed Web of Science ®Google Scholar
• Heitland W, Schädlich PK, Chen X, et al. Annual cost of hospitalization, inpatient rehabilitation and sick leave of anal cancer in Germany. J Med Econom 2013;16:364-71
   PubMedGoogle Scholar
• Klussmann JP, Schädlich PK, Chen X, et al. Annual cost of hospitalization, inpatient rehabilitation, and sick leave of head and neck cancers in Germany. ClinicoEconom Outcomes Res 2013; accepted for publication
   Google Scholar
• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81
   PubMed Web of Science ®Google Scholar
• Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 2008;11:791-9
   PubMed Web of Science ®Google Scholar
• Hu D, Goldie SJ. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008;198:500-7
   PubMed Web of Science ®Google Scholar
• Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-9
   PubMed Web of Science ®Google Scholar
• Szucs TD, Dedes KJ. Balancing costs and benefits in cancer therapy and prevention. Ann Oncol 2008;19(7 Suppl):vii313-9
   Google Scholar
• Olsen J, Jorgensen TR, Rubek N. The economic burden of head and neck cancers in Denmark. Int J Otolaryngol Head Neck Cancers 2013 ; accepted for publication
   Google Scholar